Learn ($)

This special US Research report individually reviewed approximately 3,500 NASDAQ (primarily) listed stocks with market caps under US$2 billion. The impetus of the project was to get a better understanding of current valuations, increase our analyst’s general knowledge of this set of companies and create a group of over 100 companies which have a threshold level of the GARP or growth at a reasonable price criterion we use to identify near and long-term investment opportunities.

The research produced a list of just over 130 stocks which we have provided statistical analysis on in the tables section. From these initial numbers and our initial review of the businesses, we produced a list of 38 stocks which we provide mini reports on detailing the businesses, current valuations, and merits as potential recommendations.

KeyStone has reviewed the public North American Cannabis market since inception. At legalization in Canada, we rejected all candidates as uninvestable due to a lack of profitability, high valuations and a significant production capacity overbuild. Over the ensuing year, Cannabis stocks across the board plummeted. In late 2019, a very select number of U.S. operating Cannabis stocks had emerged into profitability and one name finally met our criteria. The stock was recommended at $15.99 and reiterated less than a month later at $13.35 as a SPEC BUY. We have since added two smaller Cannabis operators in the U.S. market.  We continued to monitor players with operations primarily in the Canadian market but broadly speaking the operational struggles continued. Within this report we conduct statistical analysis on 31 Canadian Cannabis Operators, break down 8-10 of the businesses in more detail and make 3 recommendations in the U.S. Cannabis space.